Compare Ascendis Pharma A/S (ASND) vs UiPath Inc (PATH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs UiPath Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while UiPath Inc trades at $11.73 (market cap $6.05B). The key difference: Ascendis Pharma A/S is far larger — about 2.9× UiPath Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, UiPath Inc nearer its low. Which is the better fit depends on your goals.
| ASND | PATH | |
|---|---|---|
Market Cap | $17.74B | $6.05B |
Sector | Health | Technology |
52-Week High | $277.18 | $19.29 |
52-Week Low | $163.32 | $9.38 |
Enterprise Value | $18.11B | $4.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
UiPath (PATH) trades at $11.68, down 1.02% on the day, with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue growing from $1.43B in 2025 to projected $1.7B in 2026, while narrowing losses from -$74M to projected $327M profit. Recent product launches like Maestro Case expand enterprise automation capabilities. Analyst consensus price target sits at $13.33, representing 14% upside potential from current levels.
PATH presents a compelling growth story with strong revenue expansion and path to profitability, though elevated valuation multiples and competitive pressures warrant caution. The stock's current pullback offers entry opportunity for investors bullish on enterprise automation adoption, with key risks including execution on AI strategy and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
